Novavax is behind its competitors in the COVID-19 vaccine race, but the biotech's vaccine is still worth keeping a close eye on because of its positive interim trial results and potential to help vaccinate other countries, according to a July 19 Kaiser Health News report.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,